Pivotal Life Sciences | Portfolio Company News

Evommune raises $50M to fund clinical trials in skin diseases

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

December 06, 2022

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

November 01, 2022

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated

October 24, 2022

Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss

October 18, 2022

Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology

October 17, 2022

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

September 26, 2022

Top-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win

August 08, 2022

1 2 3